

## Chapter 91

### REFERENCES

1. Trescot A, Glaser S, Hansen H, et al. Effectiveness of opioids in the treatment of chronic non-cancer pain. *Pain Physician*. 2008; 11:S181-S200.
2. Woolf CJ, Bennett GJ, Doherty M, et al. Towards a mechanism-based classification of pain. *Pain*. 1998;77:227-229.
3. Woolf CJ, Max MB. Mechanism-based pain diagnosis. Issues for analgesic drug development. *Anesthesiology*. 2001;95:241-249.
4. Gheld of ELM, Vinck J, Vlaeyen JWS, et al. The differential role of pain, work characteristics and pain-related fear in explaining back pain and sick leave in occupational settings. *Pain*. 2005;113:71-81.
5. Vlaeyen JWS, Crombez G. Fear of movement/(re)injury, avoidance and pain disability in chronic low back pain patients. *Man Ther*. 1999;4:187-195.
6. Saper JR, Lake AE III. Borderline personality disorder and the chronic headache patient: review and management recommendations. *Headache*. 2002;42:663-674.
7. Waddell G, Main CJ. Assessment of severity in low-back disorders. *Spine*. 1984;9:204-208.
8. Ransford AO, Cairns D, Mooney V. The pain drawing as an aid to the psychologic evaluation of patients with low back pain. *Spine*. 1976;1:127-134.
9. Waddell G, McCulloch JA, Kummel E, et al. Non organic physical signs in low back pain. *Spine*. 1980;5:117-125.
10. Maus TP. Imaging of the spine and nerve roots. *Phys Med Rehabil Clin North Am*. 2002;13:487-544.
11. Jensen MC, Brant-Zawadzki MN, Obuchowski N, et al. Magnetic resonance imaging of the lumbar spine in people without back pain. *N Engl J Med*. 1994;331:69-73.
12. Raja SN, Haythornthwaite JA. Combination therapy for neuropathic pain—which drugs, which combination, which patients? *N Engl J Med*. 2005;352:1373-1375.
13. Farrar JT, Young JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain*. 2001;94:149-158.
14. Botney M, Fields HL. Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. *Ann Neurol*. 1983;13:160-164.
15. Reynolds IJ, Miller RJ. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. *Br J Pharmacol*. 1988;95:95-102.
16. Eisenach JC, Gebhart GF. Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. *Anesthesiology*. 1995;83:1046-1054.
17. Gerner P, Haderer AE, Mujtaba M, et al. Assessment of differential blockade by amitriptyline and its N-methyl derivative in different species by different routes. *Anesthesiology*. 2003;98:1484-1490.
18. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. *Neurology*. 1987;37:589-596.
19. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. *N Engl J Med*. 1992; 326:1250-1256.
20. Vestergaard K, Andersen G, Jensen TS. Treatment of central post-stroke pain with a selective serotonin reuptake inhibitor. *Eur J Neurol*. 1996;3(Suppl 5):169.
21. Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. *Clin Pharmacol Ther*. 1992;52:547-552.
22. Sindrup SH, Gram LF, Brøsen K, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. *Pain*. 1990;42:135-144.
23. Berger A. Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy *Clin J Pain*. 2007;23(3): 251-258.
24. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. *JAMA*. 1998;279:287-291.
25. Kvinesdal B, Molin J, Frøland A, et al. Imipramine treatment of painful diabetic neuropathy. *JAMA*. 1984;251:727-730.
26. Watson CP, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. *Neurology*. 1998;51:1166-1171.
27. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia. A randomized, placebo-controlled trial. *Neurology*. 2002; 59:1015-1021.
28. Max MB, Kishore-Komar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. *Pain*. 1991;45:3-9.
29. Watson CP, Evan RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. *Neurology*. 1982;32:671-673.
30. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. *J Pain Symptom Manage*. 1997;13: 327-331.

31. Sindrup SH, Jensen TS. Review article: Efficacy of pharmacological treatments of neuropathic pain: an update in effect related to mechanism of drug action. *Pain*. 1999;83:389-400.
32. Cai Z, McCaslin PP. Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate- and N-methyl-D-aspartate-induced intracellular Ca<sup>2+</sup> levels in neuronal culture. *Eur J Pharmacol*. 1992;219:53-57.
33. Sawynok J, Reid A. Peripheral interactions between dextromethorphan, ketamine and amitriptyline on formalin-evoked behaviors and paw edema in rats. *Pain*. 2003;102:179-186.
34. Fridrich P, Eappen S, Jaeger W, et al. Phase Ia and Ib study of amitriptyline for ulnar nerve block in humans: side effects and efficacy. *Anesthesiology*. 2004;100:1511-1518.
35. Cardenas D, Warms CA, Turner JA, et al. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. *Pain*. 2002; 96:365-373.
36. Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial. *Lancet*. 2009;374:9697:1252-1261.
37. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized controlled trial. *Neurology*. 2003;60:1284-1289.
38. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. *Neurology*. 2001;57:1583-1588.
39. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. *Pain*. 2008;136(3):432-444.
40. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. *Arthritis Rheum*. 2004;50(9):2974-2984.
41. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. *Pain*. 2005;116:109-118.
42. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once daily in the treatment of painful physical symptoms in patients with major depressive disorder. *J Psychiatr Res*. 2005;39:43-53.
43. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. *J Rheumatol*. 2009;36:398-409.
44. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. *Clin Ther*. 2008;30:1988-2004.
45. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in U.S.: 1980 vs 2000. *Pain*. 2004;109:514-519.
46. The use of opioids for the treatment of chronic pain: a consensus statement. American Academy of Pain Medicine and American Pain Society. *Clin J Pain*. 1997;13:6-8.
47. Jacox A, Carr DB, Payne R, et al. Management of cancer pain. AHCPR Publication No. 94-0592. Rockville, MD: U.S. Department of Health and Human Services, Agency for Health Care Policy and Research; 1994.
48. Gilson AM, Ryan KM, Joranson DE, et al. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. *J Pain Symptom Manage*. 2004;28:176-188.
49. Zacny J, Bigelow G, Compton P, et al. College on problems of drug dependence task force on prescription opioid non-medical use and abuse: position statement. *Drug Alcohol Depend*. 2003;69:215-232.
50. Joranson DE, Gilson AM. Drug crime is a source of abused pain medications in the United States. *J Pain Symptom Manage*. 2005;30:299-301.
51. Rowbothan MC, Twilling L, Davies PS, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. *N Engl J Med*. 2003;348:1223-1232.
52. Saper JR, Lake AE III, Hamel RL, et al. Daily scheduled opioids for intractable head pain. *Neurology*. 2004;62:1687-1694.
53. Von Korff M, Deyo RA. Potent opioids for chronic musculoskeletal pain: flying blind? *Pain*. 2004;109:207-209.
54. Trescot A, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians (ASIPP) guidelines. *Pain Physician*. 2008;11:S5-S62.
55. Fishman SM, Bandman TB, Edwards A, et al. The opioid contract in the management of chronic pain. *J Pain Symptom Manage*. 1999;18:27-37.
56. Ballantyne JC, Mao J. Opioid therapy for chronic pain. *N Engl J Med*. 2003;349:1943-1953.
57. Rajagopal A, Vassilopoulou-Sellin R, Palmer L, et al. Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. *J Pain Symptom Manage*. 2003;26:1055-1061.
58. Abs R, Verhelst J, Maeyert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. *J Clin Endocrinol Metab*. 2000;85:2215-2222.
59. Sacerdote P, Manfredi B, Mantegazza P, et al. Antinociceptive and immunosuppressive effects of opioid drugs: a structure-related activity study. *Br J Pharmacol*. 1997;121:834-840.
60. Roy S, Loh HH. Effects of opioids on the immune system. *Neurochem Res*. 1996;21:1375-1386.
61. Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. *Pain*. 2004;110:385-392.
62. Fields HL, Vanegas H, Hentall I, et al. Evidence that disinhibition of brain stem neurones contributes to morphine analgesia. *Nature*. 1983;306:684-686.
63. Heinricher MM, McGaraughty S, Tortorici V. Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla. *J Neurophysiol*. 2001;85:280-286.
64. Xie JY, Herman DS, Stiller C-O, et al. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. *J Neurosci*. 2005;25:409-416.
65. Vanderah TW, Suenaga NM, Ossipov MH, et al. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. *J Neurosci*. 2001;21:279-286.
66. Gardell LR, Wang R, Burgess SE, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. *J Neurosci*. 2002;22:6747-6755.

67. Ossipov MH, Lai J, King T, et al. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. *Biopolymers*. 2005;80:319-324.
68. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. *J Neurosci*. 1994;14:2301-2312.
69. Thomas J. Methylnaltrexone for opioid-induced constipation in advanced illness. *N Engl J Med*. 2008;358(22):2332-2343.
70. Paulson DM, Kennedy DT, Donovan RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction—a 21-day treatment-randomized clinical trial. *J Pain*. 2005;6(3):184-192.
71. Yuan CS, Doshan H, Charney MR, et al. Tolerability gut effects and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. *J Clin Pharmacol*. 2005;45:538-546.
72. Clinical Practice Guideline No. 2. *Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis*. 2nd ed. Glenview, IL: American Pain Society; 2002.
73. Weissman DE, Haddox JD. Opioid pseudo-addiction: an iatrogenic syndrome. *Pain*. 1989;36:363-366.
74. Pereira J, Lawlor P, Vigano A, et al. Equi-analgesic dose ratios for opioids: a critical review. *J Pain Symptom Manage*. 2001;22:672-687.
75. Pasternak GW. The pharmacology of mu analgesics: from patients to genes. *Neuroscientist*. 2001;7:220-231.
76. Cicero TJ. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). *Pain Med*. 2007;8(2):157-170.
77. US Food and Drug Administration. Opioid Drugs and Risk Evaluation and Mitigation Strategies (REMS). FDA Reviews Docket Submissions and Comments from Stakeholder and Public Meetings (Update November 2009). <http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm>.
78. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. *Neurology*. 1998;50:1837-1841.
79. Sindrup SH, Andersen U, Madsen C, et al. Tramadol relieve pain and allodynia in polyneuropathy. A randomized, double-blind, placebo-controlled trial. *Pain*. 1999;83:85-90.
80. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin or their combination for neuropathic pain. *N Engl J Med*. 2005;352:1324-1334.
81. Rowbotham MC, Reisner KL, Fields HL. Both intravenous lidocaine and morphine reduce the pain of post-herpetic neuralgia. *Neurology*. 1991;41:1024-1028.
82. Wu CL, Tella P, Staats P, et al. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double-blind, active placebo-controlled, crossover trial. *Anesthesiology*. 2002;96:841-848.
83. Afilalo M, Kuperwasser B, Kelly K, et al. Efficacy and safety of tapentadol extended release (ER) for chronic pain due to osteoarthritis of the knee: results of a phase 3 study. Poster presented at: 5th World Congress of the World Institute of Pain (WIP); March 13-16, 2009; New York, New York, USA. *Pain Practice*. 2009;(9 Suppl S1):159.
84. Buynak R, Shapiro D, Okamoto A, et al. Efficacy and safety of tapentadol extended-release for chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. Poster presented at: 28th Annual Scientific Meeting of the American Pain Society (APS); May 7-9, 2009; San Diego, CA. *USA J Pain*. 2009;10 (4 Suppl 1):S50.
85. Etropolski M, Shapiro D, Okamoto A, et al. Efficacy and safety of tapentadol extended release (ER) for diabetic peripheral neuropathic pain: results of a randomized-withdrawal, double-blind, placebo-controlled phase III study. Poster presented at: 61st Annual Meeting of the American Academy of Neurology (AAN); April 25-May 2, 2009; Seattle, WA.
86. Lange C, Lange R, Kuperwasser B, et al. Long-term safety of controlled; adjustable doses of tapentadol extended release and oxycodone controlled release: results of a randomized, open-label, phase 3, 1-year trial in patients with chronic low back or osteoarthritis pain. Poster presented at: 10th Annual Congress of the European League Against Rheumatism (EULAR); June 10-13, 2009; Copenhagen, Denmark. *Ann Rheum Dis*. 2009;68(Suppl 3):698.
87. Gorman AL, Elliott KJ, Inturrisi CE. The *d*- and *l*-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. *Neurosci Lett*. 1997;223:5-8.
88. Davis AM, Inturrisi CE. *d*-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. *J Pharmacol Exp Ther*. 1999;289:1048-1053.
89. Ripamonti C, Groff L, Brunelli C, et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? *J Clin Oncol*. 1998;16:3216-3221.
90. Morley JS, Makin MK. The use of methadone in cancer pain poorly responsive to other opioids. *Pain Rev*. 1998;5:51-58.
91. Walker PW, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. *Pain*. 2003;103:321-324.
92. Fitzgibbon EJ, Hall P, Schroder C, et al. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. *J Pain Symptom Manage*. 2002;23:165-170.
93. Eide PK, Jørum E, Stubhaug A, et al. Relief of postherpetic neuralgia with the NMDA receptor antagonist ketamine: a double-blind cross-over comparison with morphine and placebo. *Pain*. 1994;58:347-354.
94. Max MB, Byas-Smith MG, Gracely RH, et al. Intravenous infusion of the NMDA antagonist, ketamine, in chronic post-traumatic pain and allodynia: a double-blind comparison to alfentanil and placebo. *Clin Neuropharmacol*. 1995;18:360-368.
95. Felsby S, Nielsen J, Arendt-Nielsen L, et al. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. *Pain*. 1996;64:283-291.
96. Eisenberg E, Kleiser A, Dortort A, et al. The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. *Eur J Pain*. 1998;2:321-327.
97. McQuay HJ, Carroll D, Jadad AR, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomized controlled crossover trial with integral N-of-1 design. *Pain*. 1994;59:127-133.
98. Pud D, Eisenberg E, Spitzer A, et al. The NMDA antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. *Pain*. 1998;75:349-354.

99. Gold MS, Weinrich D, Kim C-S, et al. Redistribution of  $Na_v$  1.8 in injured axons enables neuropathic pain. *J Neurosci*. 2003;23:158-166.
100. Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion alpha-2 delta calcium channel subunit and its correlation with allodynia in spinal nerve injured rats. *J Neurosci*. 2001;21:1868-1875.
101. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. A randomized controlled trial. *JAMA*. 2004;291:63-70.
102. Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbamazepine (Tegretol) in trigeminal neuralgia. *J Neurol Neurosurg Psychiatry*. 1966;29:265-267.
103. Porter RJ, Meldrum BS. Antiseizure drugs. In: Katzung BG, ed. *Basic and Clinical Pharmacology*. 9th ed. New York, NY: McGraw-Hill; 2004:383-384.
104. Burchiel KJ. Carbamazepine inhibits spontaneous activity in experimental neuromas. *Exp Neurol*. 1988;102:249.
105. Rull JA, Quibrera R, Gonzalez-Millan H, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind cross over trial. *Diabetologia*. 1969;5:215-218.
106. Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use and side effects. *Arch Neurol*. 1968;19:129-136.
107. Beydoun A, Kobetz S, Carrazana E. Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. *Clin J Pain*. 2004;20:174-178.
108. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. *J Pain Symptom Manage*. 2003;25:S31-S35.
109. Zakrewska JM, Patsolos PN. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. *J Neurol Neurosurg Psychiatry*. 1989;52:472-476.
110. Silberstein SD, Neto W, Schmitt J, et al, for the MIGR-001 Study Group. Topiramate in migraine prevention. Results of a large controlled trial. *Arch Neurol*. 2004;61:490-495.
111. Brandes JL, Saper JL, Diamond M, et al, for the MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. *JAMA*. 2004;291:965-973.
112. Thienel U, Neto W, Schwabe SK, et al, for the Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. *Acta Neurol Scand*. 2004;110:221-231.
113. Raskin P, Donofrio PD, Rosenthal NR, et al, for the CAPSS-141 Study Group. Topiramate vs placebo in painful diabetic neuropathy. Analgesic and metabolic effects. *Neurology*. 2004;63:865-873.
114. Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate treated epilepsy. *Obes Res*. 2003;11:556-562.
115. Gee NS, Brown JP, Dissanayake BU, et al. The novel anticonvulsant drug gabapentin binds to the alpha-2 delta-1 subunit of the calcium channel. *J Biol Chem*. 1996;271:5768-5776.
116. Mellick GA, Mellick LB. Gabapentin in the management of reflex sympathetic dystrophy. *J Pain Symptom Manage*. 1995;10:265-266.
117. Backonja M, Beydoun A, Edwards KR, et al, for the Gabapentin Diabetic Neuropathy Study Group. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. A randomized controlled trial. *JAMA*. 1998;280:1831-1836.
118. Dallocchio C, Buffa C, Mazzarello P, et al. Gabapentin vs amitriptyline in painful diabetic neuropathy: an open label pilot study. *J Pain Symptom Manage*. 2000;20:280-285.
119. Morello CM, Luckband SG, Stoner CP, et al. Randomized double blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. *Arch Intern Med*. 1999;159:1931-1937.
120. Gorson KC, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy. A placebo-controlled double blind crossover trial. *J Neurol Neurosurg Psychiatry*. 1999;66:251-252.
121. Rice AS, Maton S. Post-herpetic neuralgia study group: gabapentin and post-herpetic neuralgia: a randomized double-blind placebo controlled study. *Pain*. 2001;94:215-224.
122. Rowbotham M, Harden N, Stacey B, et al, for the Gabapentin Study Group. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. *JAMA*. 1998;280:1837-1842.
123. Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal calcium influx by gabapentin and pregabalin in the human neocortex. *Neuropharmacology*. 2002;42:229-236.
124. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomized placebo-controlled clinical trial. *Pain*. 2004;109:26-35.
125. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double blind, placebo-controlled trial. *Pain*. 2004;110:628-638.
126. Margineanu DG, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. *Pharmacol Res*. 2000;42:281-285.
127. Price MJ. Levetiracetam in the treatment of neuropathic pain: 3 case studies. *Clin J Pain*. 2004;20:33-36.
128. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: a randomized controlled study. *Neurology*. 2001;57:505-509.
129. Simpson DM, Olney R, McArthur JC, et al. A placebo controlled trial of lamotrigine for painful HIV-associated neuropathy. *Neurology*. 2000;54:2115-2119.
130. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al. Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double blind placebo controlled trial. *Pain*. 1997;73:223-230.
131. Finnerup NB, Sindrup SH, Bach FW, et al. Lamotrigine in spinal cord injury pain: a randomized controlled trial. *Pain*. 2002;96:375-383.
132. Todorov AA, Kolchev CB, Todorov AB. Tiagabine and gabapentin for the management of chronic pain. *Clin J Pain*. 2005;21:358-361.
133. Chadda VS, Mathur MS. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. *J Assoc Physicians India*. 1978;26:403-406.
134. McCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized double-blinded, placebo-controlled, crossover study. *Anesth Analg*. 1999;89:985-988.
135. Lynch ME, Clark AJ, Sawyonok J, et al. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes. *Anesthesiology*. 2005;103:140-146.

136. Lockhart E. Topical combination of amitriptyline ketamine for postherpetic neuralgia. *J Pain*. 2004;5(S1):82.
137. D'Onofrio P, Walker F, et al; Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. *Arch Intern Med*. 1991;151:2225-2229.
138. Bernstein IF, Kornman NJ, Bickers DR, et al. Topical capsaicin treatment of chronic postherpetic neuralgia. *J Am Acad Dermatol*. 1989;21:265-270.
139. Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. *Pain*. 1992;48:261-268.
140. Woolf CJ, Wiesenfeld-Hallin Z. The systemic administration of local anesthetics produces the selected depression of C-afferent fiber evoked activity in the spinal cord. *Pain*. 1995;23:361-374.
141. Finnerup NB, Biering-Sorensen F, Johannesen IL, et al. Intravenous lidocaine relieves spinal cord injury pain. A randomized controlled trial. *Anesthesiology*. 2005;102:1023-1030.
142. Kastrup J, Angelo H, Peterson P, et al. Treatment of chronic pain diabetic neuropathy with intravenous lidocaine infusion. *BMJ*. 1986;292:173.
143. Kastrup J, Petersen P, Dejgård A, et al. Intravenous lidocaine infusion—a new treatment of chronic painful diabetic neuropathy? *Pain*. 1987;28:69-75.
144. Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. *J Pain Symptom Manage*. 1996;12:161-167.
145. Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. *Lancet*. 1988;1:8575-8576.
146. Trevor AJ, Way WL. Sedative-hypnotic drugs. In: Katzung BG, ed. *Basic and Clinical Pharmacology*. 9th ed. New York, NY: McGraw-Hill; 2004:353-354.
147. Yegin A, Sanli S, Dosemeci L, et al. The analgesic and sedative effects of intrathecal midazolam in perianal surgery. *Eur J Anesthesiol*. 2004;21:658-662.
148. Gremeau-Richard C, Woda A, Navez ML, et al. Topical clonazepam in stomatodynia: a randomized placebo-controlled study. *Pain*. 2004;108:51-57.
149. Eisele JH, Grigsby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. *Pain*. 1992;49:231-232.
150. Freitag FG. Preventative treatment for migraine and tension-type headaches: do drugs having effects on muscle spasm and tone have a role? *CNS Drugs*. 2003;17:373-381.
151. Meythaler JM, Guin-Renfroe S, Johnson A, et al. Prospective assessment of tizanidine for spasticity due to acquired brain injury. *Arch Phys Med Rehabil*. 2001;82:1155-1163.
152. Slonimski M, Abram SE, Zuniga RE. Intrathecal baclofen in pain management. *Reg Anesth Pain Med*. 2004;29:269-276.
153. Fromm GH, Terrence CF. Comparison of L-baclofen and racemic baclofen in trigeminal neuralgia. *Neurology*. 1987;37:1725-1728.
154. Childers MK, Borenstein D, Brown RL, et al. Low-dose cyclobenzaprine versus combination therapy with ibuprofen for acute neck or back pain with muscle spasm: a randomized trial. *Curr Med Res Opin*. 2005;21:1485-1493.
155. Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. *Clin Ther*. 2004;26:1355-1367.
156. Van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for non-specific low back pain: a systematic review within the framework of the Cochrane Collaboration. *Spine*. 2003;17:1978-1992.
157. Bramness JG, Skurtveit S, Morland J. Impairment due to intake of carisoprodol. *Drug Alcohol Depend*. 2004;74:311-318.
158. Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal anti-inflammatory drugs. *Arthritis Rheum*. 1985;28:686-692.
159. Pilotto A, Franceschi M, Leandro G, et al, on behalf of the Geriatric Gastroenterology Study Group. NSAID and aspirin use by the elderly in general practice. *Drugs Aging*. 2003;20:701-710.
160. Wagner W, Khanna P, Furst DE. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, and drugs used in gout. In: Katzung BG, ed. *Basic and Clinical Pharmacology*. 9th ed. New York, NY: McGraw-Hill; 2004:576-577.
161. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. *N Engl J Med*. 2000;343:1520-1528.
162. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. *JAMA*. 2000;284:1247-1255.
163. Bresalier RS, Sandler RS, Quan H, et al, for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med*. 2005;352:1092-1102.
164. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. *N Engl J Med*. 2005;352:1081-1091.
165. American Pain Society. *Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis*. 2nd ed. Glenview, IL: American Pain Society; 2002.
166. Reijman M, Bierma-Zeinstra SMA, Pols HA, et al. Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. *Arthritis Rheum*. 2005;52:3137-3142.
167. Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. *BMC Musculoskel Disord*. 2004;5:28.
168. Chandrasekharan NV, Dai H, Roos KLT, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc Natl Acad Sci U S A*. 2002;99:13926-13931.
169. Sandrini M, Vitale G, Pini LA, et al. Nociceptin/orphanin FQ prevents the antinociceptive action of paracetamol on the rat hot plate test. *Eur J Pharmacol*. 2005;507:43-48.
170. Bradley JD, Brandt KD, Katz BP, et al. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal anti-inflammatory drug or pure analgesic. *J Rheumatol*. 1992;19:1950-1954.
171. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee. *JAMA*. 2002;287:64-71.
172. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. *Am J Ther*. 2005;12:133-141.

173. Gallagher RM. Rational integration of pharmacologic, behavioral, and rehabilitation strategies in the treatment of chronic pain. *Am J Phys Med Rehabil.* 2005;84:S64-S76.
174. Lemstra M, Olszyuski WP. The effectiveness of multidisciplinary rehabilitation in the treatment of fibromyalgia: a randomized controlled trial. *Clin J Pain.* 2005;21:161-176.
175. Hooten WM, Townsend CO, Bruce BK, et al. Treatment outcomes after multidisciplinary pain rehabilitation with analgesic medication withdrawal for patients with fibromyalgia. *Pain Med.* 2007;8:8-16.
176. Rome JD, Townsend CO, Bruce BK, et al. Chronic noncancer pain rehabilitation with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission and colleagues. *Mayo Clin Proc.* 2004;79:759-768.
177. Robbins H, Gatchel RJ, Noe C, et al. A prospective one-year outcome study of interdisciplinary chronic pain management: compromising its efficacy by managed care policies. *Anesth Analg.* 2003;97:156-162.
178. Deyo RA, Nachemson A, Mirza SK. Spinal fusion surgery: the case for restraint. *N Engl J Med.* 2004;350:722-726.
179. Brox JJ, Sørensen R, Friis A, et al. Randomized clinical trial of lumbar instrumented fusion and cognitive intervention and exercises in patients with chronic low back pain and disc degeneration. *Spine.* 2003;17:1913-1921.
180. Fairbank J, Frost H, Wilson-MacDonald J, et al. Randomised controlled trial to compare surgical stabilization of the lumbar spine with an intensive rehabilitation programme for patients with chronic low back pain: the MRC spine stabilization trial. *BMJ.* 2005;330:1233-1239.
181. Rivero-Arias O, Campbell H, Gray A, et al, and Spine Stabilisation Trial Group. Surgical stabilisation of the spine compared with a programme of intensive rehabilitation for the management of patients with chronic low back pain: cost utility analysis based on a randomised controlled trial. *BMJ.* 2005;330:1239-1243.
182. Sullivan MJL, Thorn B, Haythornwaite JA, et al. Theoretical perspectives on the relation between catastrophizing and pain. *Clin J Pain.* 2001;17:52-64.
183. Fillingim RB, Doleys DM, Edwards RR, et al. Clinical characteristics of chronic back pain as a function of gender and oral opioid use. *Spine.* 2003;28:143-150.
184. Novy DM. Psychological approaches for managing chronic pain. *J Psychopathol Behav Assess.* 2004;26:279-288.
185. de Jong JR, Vlaeyen JWS, Onghena J, et al. Fear of movement/(re)injury in chronic low back pain. Education or exposure in vivo as mediator to fear reduction? *Clin J Pain.* 2005;21:9-17.
186. Hayden JA, van Tulder M W, Tomlinson G. Systematic review: Strategies for using exercise therapy to improve outcomes in chronic low back pain. *Ann Intern Med.* 2005;142:776-785.
187. Rakel B, Barr J. Physical modalities in chronic pain management. *Nurs Clin North Am.* 2003;38:477-494.
188. Denys EH. AAEM Minimonograph #14: the influence of temperature in clinical neurophysiology. *Muscle Nerve.* 1991;14:795-811.
189. Melzack R, Jeans ME, Stratford JG, et al. Ice massage and transcutaneous electrical stimulation: comparison of treatment for low back pain. *Pain.* 1980;9:209-217.
190. Dellahg B, Wollersjo I, Bjelle A. Effect of active hand exercise and wax bath treatment in rheumatoid arthritis patients. *Arthritis Care Res.* 1992;5:87-92.
191. Hall J, Skevington SM, Maddison PJ, et al. A randomized and controlled trial of hydrotherapy in rheumatoid arthritis. *Arthritis Care Res.* 1996;9:206-215.
192. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. *Drug Deliv.* 2006;13:175-187.
193. Kaptchuk T. Acupuncture: theory, efficacy and practice. *Ann Intern Med.* 2002;136:374-484.
194. Han JS. Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies. *Trends Neurosci.* 2003;26:17-22.
195. Lewith G, White P, Pariente J. Investigating acupuncture using brain imaging techniques: the current state of play. *Evid Based Complement Alternat Med.* 2005;2:315-319.
196. Yan B, Li K, Wang W, et al. Acupoint-specific fMRI patterns in human brain. *Neurosci Lett.* 2005;383:236-240.
197. Birch S, Hesselink JK, Jonkman FA, et al. Clinical research on acupuncture. Part 1. What have reviews of the efficacy and safety of acupuncture told us so far? *J Alternat Complement Med.* 2004;10:468-480.
198. Assefi NP, Sherman KJ, Jacobsen C, et al. A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia. *Ann Intern Med.* 2005;143:10-19.
199. Acupuncture: NIH Consensus Conference. *JAMA.* 1998;280:1518-1524.